Wnt	B-GP
signalling	O
modulates	O
transcribed	O
-	O
ultraconserved	O
regions	O
in	O
hepatobiliary	B-DS
cancers	I-DS

Part	O
of	O
these	O
data	O
has	O
been	O
presented	O
at	O
the	O
International	O
Liver	B-DS
Cancer	I-DS
Association	O
Annual	O
Meeting	O
2013	O
and	O
2014	O
(	O
available	O
online	O
at	O
http	O
://	O
www	O
.	O
ilca	O
-	O
online	O
.	O
org	O
/	O
annual	O
-	O
conferences	O
),	O
the	O
2013	O
NCRI	O
Cancer	B-DS
Conference	O
Meeting	O
(	O
available	O
online	O
at	O
http	O
://	O
conference	O
.	O
ncri	O
.	O
org	O
.	O
uk	O
)	O
and	O
the	O
EASL	O
Liver	O
Meeting	O
2014	O
(	O
Journal	O
of	O
Hepatology	O
,	O
Vol	O
.	O

60	O
,	O
Issue	O
1	O
,	O
S88	O
)	O
and	O
2015	O
(	O
Journal	O
of	O
Hepatology	O
,	O
Vol	O
.	O

62	O
,	O
S413	O
–	O
S414	O
).	O

Transcript	O
profiling	O
:	O
GSE78911	O
(	O
mice	B-OG
lncRNA	O
-	O
T	O
-	O
UCR	O
profiling	O
),	O
GSE25859	O
(	O
human	B-OG
cell	O
lines	O
lncRNA	O
-	O
T	O
-	O
UCR	O
profiling	O
),	O
GSE78912	O
(	O
miRNA	O
mice	B-OG
profiling	O
).	O

Objective	O

Transcribed	O
-	O
ultraconserved	O
regions	O
(	O
T	O
-	O
UCR	O
)	O
are	O
long	O
non	O
-	O
coding	O
RNAs	O
which	O
are	O
conserved	O
across	O
species	O
and	O
are	O
involved	O
in	O
carcinogenesis	O
.	O

We	O
studied	O
T	O
-	O
UCRs	O
downstream	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
liver	B-DS
cancer	I-DS
.	O

Design	O

Hypomorphic	O
Apc	B-GP
mice	B-OG
(	O
Apcfl	O
/	O
fl	O
)	O
and	O
thiocetamide	O
(	O
TAA	O
)-	O
treated	O
rats	B-OG
developed	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
dependent	O
hepatocarcinoma	B-DS
(	O
HCC	B-DS
)	O
and	O
cholangiocarcinoma	B-DS
(	O
CCA	B-DS
),	O
respectively	O
.	O

T	O
-	O
UCR	O
expression	O
was	O
assessed	O
by	O
microarray	O
,	O
real	O
-	O
time	O
PCR	O
and	O
in	O
situ	O
hybridisation	O
.	O

Results	O

Overexpression	O
of	O
the	O
T	O
-	O
UCR	O
uc	O
.	O
158	O
−	O
could	O
differentiate	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
dependent	O
HCC	B-DS
from	O
normal	O
liver	O
and	O
from	O
β	B-GP
-	I-GP
catenin	I-GP
negative	O
diethylnitrosamine	O
(	O
DEN	O
)-	O
induced	O
HCC	B-DS
.	O
uc	O
.	O
158	O
−	O
was	O
overexpressed	O
in	O
human	B-OG
HepG2	O
versus	O
Huh7	O
cells	O
in	O
line	O
with	O
activation	O
of	O
the	O
Wnt	B-GP
pathway	O
.	O

In	O
vitro	O
modulation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
altered	O
uc	O
.	O
158	O
−	O
expression	O
in	O
human	B-OG
malignant	O
hepatocytes	O
.	O
uc	O
.	O
158	O
−	O
expression	O
was	O
increased	O
in	O
CTNNB1	B-GP
-	O
mutated	O
human	B-OG
HCCs	B-DS
compared	O
with	O
non	O
-	O
mutated	O
human	B-OG
HCCs	B-DS
,	O
and	O
in	O
human	B-OG
HCC	B-DS
with	O
nuclear	O
localisation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
.	O
uc	O
.	O
158	O
−	O
was	O
increased	O
in	O
TAA	O
rat	B-OG
CCA	B-DS
and	O
reduced	O
after	O
treatment	O
with	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
inhibitors	O
.	O
uc	O
.	O
158	O
−	O
expression	O
was	O
negative	O
in	O
human	B-OG
normal	O
liver	O
and	O
biliary	O
epithelia	O
,	O
while	O
it	O
was	O
increased	O
in	O
human	B-OG
CCA	B-DS
in	O
two	O
different	O
cohorts	O
.	O

Locked	O
nucleic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
uc	O
.	O
158	O
−	O
reduced	O
anchorage	O
cell	O
growth	O
,	O
3D	O
-	O
spheroid	O
formation	O
and	O
spheroid	O
-	O
based	O
cell	O
migration	O
,	O
and	O
increased	O
apoptosis	O
in	O
HepG2	O
and	O
SW1	O
cells	O
.	O

miR	O
-	O
193b	O
was	O
predicted	O
to	O
have	O
binding	O
sites	O
within	O
the	O
uc	O
.	O
158	O
−	O
sequence	O
.	O

Modulation	O
of	O
uc	O
.	O
158	O
−	O
changed	O
miR	O
-	O
193b	O
expression	O
in	O
human	B-OG
malignant	O
hepatocytes	O
.	O

Co	O
-	O
transfection	O
of	O
uc	O
.	O
158	O
−	O
inhibitor	O
and	O
anti	O
-	O
miR	O
-	O
193b	O
rescued	O
the	O
effect	O
of	O
uc	O
.	O
158	O
−	O
inhibition	O
on	O
cell	O
viability	O
.	O

Conclusions	O

We	O
showed	O
that	O
uc	O
.	O
158	O
−	O
is	O
activated	O
by	O
the	O
Wnt	B-GP
pathway	O
in	O
liver	B-DS
cancers	I-DS
and	O
drives	O
their	O
growth	O
.	O

Thus	O
,	O
it	O
may	O
represent	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
novel	O
therapeutics	O
.	O

Summary	O
box	O

What	O
is	O
already	O
known	O
on	O
this	O
subject	O
?	O

The	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
is	O
frequently	O
activated	O
in	O
liver	B-DS
cancer	I-DS
.	O

The	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
Wnt	B-GP
deregulation	O
is	O
necessary	O
to	O
develop	O
more	O
specific	O
and	O
effective	O
therapeutics	O
.	O

Transcribed	O
-	O
ultraconserved	O
regions	O
(	O
T	O
-	O
UCRs	O
)	O
are	O
long	O
non	O
-	O
coding	O
RNAs	O
that	O
harbour	O
ultraconserved	O
elements	O
and	O
are	O
altered	O
in	O
human	B-OG
carcinomas	B-DS
.	O

What	O
are	O
the	O
new	O
findings	O
?	O

We	O
demonstrate	O
that	O
T	O
-	O
UCRs	O
are	O
downstream	O
mediators	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
three	O
different	O
species	O
,	O
and	O
we	O
provide	O
evidence	O
of	O
their	O
role	O
as	O
competing	O
endogeneous	O
long	O
non	O
-	O
coding	O
RNAs	O
.	O

We	O
have	O
identified	O
a	O
mediator	O
that	O
is	O
downstream	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
and	O
specific	O
for	O
cancer	B-DS
development	O
,	O
improving	O
the	O
development	O
of	O
effective	O
and	O
selective	O
novel	O
therapeutics	O
.	O

How	O
might	O
it	O
impact	O
on	O
clinical	O
practice	O
in	O
the	O
foreseeable	O
future	O
?	O

We	O
have	O
studied	O
several	O
cohorts	O
of	O
human	B-OG
liver	B-DS
cancers	I-DS
and	O
observed	O
that	O
deregulation	O
of	O
uc	O
.	O
158	O
−	O
is	O
shared	O
between	O
hepatocarcinoma	B-DS
and	O
cholangiocarcinoma	B-DS
,	O
providing	O
interesting	O
insights	O
into	O
the	O
molecular	O
biology	O
of	O
these	O
diseases	O
and	O
the	O
implication	O
for	O
clinical	O
trial	O
design	O
.	O

Background	O

Hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
is	O
the	O
sixth	O
most	O
common	O
malignancy	O
in	O
the	O
world	O
.	O
1	O
Despite	O
the	O
progress	O
of	O
recent	O
decades	O
,	O
the	O
outcome	O
of	O
patients	O
with	O
advanced	O
HCC	B-DS
remains	O
poor	O
,	O
and	O
mortality	O
for	O
liver	B-DS
cancer	I-DS
has	O
increased	O
worldwide	O
.	O
1	O
Sorafenib	O
is	O
the	O
only	O
drug	O
which	O
is	O
effective	O
in	O
advanced	O
HCC	B-DS
with	O
an	O
improvement	O
of	O
about	O
3	O
months	O
in	O
median	O
overall	O
survival	O
.	O
2	O
Novel	O
therapies	O
are	O
urgently	O
needed	O
,	O
but	O
their	O
development	O
is	O
challenged	O
by	O
the	O
limited	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
HCC	B-DS
progression	O
and	O
the	O
subsequent	O
lack	O
of	O
identified	O
targets	O
that	O
drive	O
liver	O
transformation	O
.	O

The	O
Wnt	B-GP
pathway	O
is	O
frequently	O
activated	O
in	O
HCC	B-DS
.	O
3	O
4	O
Various	O
attempts	O
have	O
been	O
made	O
to	O
develop	O
therapeutics	O
targeting	O
the	O
Wnt	B-GP
pathway	O
components	O
,	O
and	O
some	O
of	O
these	O
are	O
now	O
under	O
clinical	O
evaluation	O
.	O
5	O
However	O
,	O
the	O
challenges	O
faced	O
in	O
the	O
development	O
of	O
Wnt	B-GP
inhibitors	O
,	O
such	O
as	O
specificity	O
and	O
toxicity	O
,	O
demand	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
Wnt	B-GP
deregulation	O
,	O
in	O
order	O
to	O
inform	O
the	O
design	O
of	O
more	O
specific	O
and	O
more	O
effective	O
compounds	O
.	O

The	O
canonical	O
Wnt	B-GP
pathway	O
(	O
or	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
)	O
leads	O
to	O
an	O
accumulation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
the	O
cytoplasm	O
that	O
can	O
be	O
translocated	O
into	O
the	O
nucleus	O
and	O
activate	O
transcription	B-GP
factors	I-GP
.	O
3	O
A	O
recent	O
analysis	O
of	O
human	B-OG
HCC	B-DS
has	O
shown	O
that	O
the	O
Wnt	B-GP
pathway	O
is	O
activated	O
in	O
49	O
%	O
of	O
HCC	B-DS
and	O
that	O
almost	O
half	O
of	O
these	O
had	O
features	O
consistent	O
with	O
the	O
activation	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
.	O
6	O
These	O
data	O
are	O
in	O
line	O
with	O
an	O
integrated	O
analysis	O
of	O
somatic	O
mutations	O
which	O
revealed	O
activating	O
mutations	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
(	O
CTNNB1	B-GP
)	O
in	O
33	O
%	O
of	O
human	B-OG
HCC	B-DS
.	O

In	O
addition	O
,	O
mutations	O
of	O
CTNNB1	B-GP
are	O
mutually	O
exclusive	O
with	O
mutations	O
in	O
AXIN1	B-GP
.	O
7	O

Non	O
-	O
coding	O
RNAs	O
(	O
ncRNA	O
)	O
are	O
implicated	O
in	O
liver	O
carcinogenesis	O
.	O
8	O
–	O
10	O
We	O
and	O
others	O
have	O
provided	O
data	O
to	O
support	O
the	O
involvement	O
of	O
small	O
ncRNAs	O
,	O
such	O
as	O
microRNAs	O
,	O
in	O
the	O
modulation	O
of	O
liver	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O
10	O
–	O
13	O
Despite	O
several	O
studies	O
linking	O
ncRNA	O
and	O
the	O
Wnt	B-GP
pathway	O
,	O
most	O
of	O
them	O
focused	O
on	O
the	O
modulation	O
of	O
Wnt	B-GP
signalling	O
proteins	O
by	O
microRNAs	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
this	O
pathway	O
on	O
ncRNA	O
.	O
14	O
–	O
17	O
Increasing	O
evidence	O
points	O
to	O
an	O
important	O
regulatory	O
role	O
of	O
long	O
ncRNAs	O
in	O
cellular	O
processes	O
and	O
disease	O
phenotypes	O
.	O

Sequence	O
conservation	O
across	O
species	O
has	O
been	O
postulated	O
to	O
indicate	O
that	O
a	O
given	O
ncRNA	O
may	O
have	O
a	O
cellular	O
function	O
.	O

A	O
genome	O
-	O
wide	O
survey	O
identified	O
481	O
genomic	O
sequences	O
with	O
a	O
size	O
>	O
200	O
bp	O
that	O
showed	O
a	O
remarkable	O
conservation	O
with	O
100	O
%	O
identity	O
across	O
human	B-OG
,	O
mouse	B-OG
and	O
rat	B-OG
genomes	O
.	O
18	O
These	O
ultraconserved	O
regions	O
(	O
UCR	O
)	O
were	O
shown	O
to	O
be	O
transcribed	O
as	O
ultraconserved	O
ncRNAs	O
(	O
T	O
-	O
UCR	O
).	O

They	O
exhibit	O
distinct	O
profiles	O
in	O
various	O
human	B-OG
cancers	B-DS
and	O
modulate	O
cellular	O
proliferation	O
and	O
apoptosis	O
.	O
19	O
–	O
25	O
We	O
have	O
previously	O
shown	O
that	O
T	O
-	O
UCRs	O
are	O
aberrantly	O
expressed	O
in	O
HCC	B-DS
and	O
have	O
a	O
role	O
in	O
the	O
malignant	O
growth	O
of	O
human	B-OG
and	O
murine	O
hepatocytes	O
.	O
25	O
In	O
this	O
study	O
,	O
we	O
aim	O
to	O
investigate	O
the	O
effect	O
of	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signalling	O
on	O
T	O
-	O
UCRs	O
in	O
order	O
to	O
find	O
downstream	O
effectors	O
of	O
this	O
pathway	O
that	O
can	O
be	O
targeted	O
for	O
the	O
development	O
of	O
novel	O
and	O
more	O
specific	O
therapeutics	O
.	O

Methods	O

Animal	B-OG
models	O

All	O
animals	B-OG
were	O
handled	O
in	O
strict	O
accordance	O
with	O
good	O
animal	B-OG
practice	O
as	O
defined	O
by	O
the	O
relevant	O
national	O
and	O
/	O
or	O
local	O
animal	B-OG
welfare	O
bodies	O
,	O
and	O
all	O
animal	B-OG
works	O
were	O
approved	O
by	O
the	O
appropriate	O
committees	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
compliance	O
with	O
UK	O
Home	O
Office	O
Animal	B-OG
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
and	O
the	O
EU	O
Directive	O
2010	O
.	O

Hypomorphic	O
mutant	O
(	O
Apc580s	O
/	O
580s	O
)	O
Apcfl	O
/	O
fl	O
mice	B-OG
were	O
used	O
and	O
compared	O
with	O
Apc	B-GP
+/+	O
mice	B-OG
.	O

Model	O
generation	O
and	O
demonstration	O
of	O
the	O
activation	O
of	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
this	O
HCC	B-DS
model	O
have	O
already	O
been	O
reported	O
.	O
26	O
We	O
extracted	O
RNA	O
from	O
the	O
liver	O
of	O
Apcfl	O
/	O
fl	O
(	O
tumour	B-DS
with	O
activation	O
of	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
)	O
and	O
Apc	B-GP
+/+	O
(	O
normal	O
liver	O
).	O
TAA	O
rat	B-OG
tumour	B-DS
model	O
was	O
used	O
as	O
a	O
model	O
of	O
rat	B-OG
cholangiocarcinoma	B-DS
(	O
CCA	B-DS
).	O

Generation	O
of	O
this	O
model	O
and	O
activation	O
of	O
Wnt	B-GP
pathway	O
in	O
this	O
tumour	B-DS
model	O
have	O
already	O
been	O
reported	O
.	O
27	O
ICG	O
-	O
001	O
(	O
5	O
mg	O
/	O
kg	O
)	O
(	O
Tocris	O
,	O
Bristol	O
,	O
UK	O
)	O
or	O
C	O
-	O
59	O
(	O
20	O
mg	O
/	O
kg	O
)	O
(	O
Cellagen	O
Technologies	O
,	O
San	O
Diego	O
,	O
California	O
,	O
USA	O
)	O
was	O
given	O
by	O
intraperitoneal	O
injection	O
.	O

The	O
vehicle	O
for	O
this	O
was	O
physiological	O
saline	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Sigma	O
,	O
St	O
Louis	O
,	O
Missouri	O
,	O
USA	O
).	O

Control	O
animals	B-OG
were	O
given	O
vehicle	O
alone	O
.	O

In	O
all	O
cases	O
,	O
inhibitors	O
and	O
vehicle	O
were	O
given	O
three	O
times	O
per	O
week	O
.	O
27	O
We	O
extracted	O
RNA	O
from	O
the	O
liver	O
of	O
TAA	O
rat	B-OG
(	O
tumour	B-DS
)	O
or	O
saline	O
control	O
(	O
normal	O
liver	O
),	O
as	O
well	O
as	O
from	O
TAA	O
rats	B-OG
treated	O
with	O
ICG	O
-	O
001	O
,	O
C59	O
or	O
saline	O
control	O
.	O
Axin1fl	O
/	O
fl	O
/	O
Cre	B-GP
mouse	B-OG
model	O
was	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
Axin1	B-GP
disruption	O
in	O
the	O
hepatocytes	O
.	O

This	O
model	O
was	O
generated	O
by	O
crossing	O
mice	B-OG
homozygous	O
for	O
the	O
Axin1fl	O
/	O
fl	O
allele	O
with	O
AhCre	O
mice	B-OG
,	O
as	O
previously	O
reported	O
.	O
28	O
We	O
extracted	O
RNA	O
from	O
the	O
liver	O
of	O
Axin1fl	O
/	O
fl	O
/	O
Cre	B-GP
and	O
Axin1	B-GP
+/+/	O
Cre	B-GP
mice	B-OG
.	O
Diethylnitrosamine	O
-	O
induced	O
HCC	B-DS
:	O
C57BL	O
/	O
6	O
,	O
14	O
days	O
old	O
male	O
mice	B-OG
were	O
intraperitoneally	O
injected	O
with	O
diethylnitrosamine	O
(	O
DEN	O
)	O
(	O
40	O
μL	O
of	O
a	O
solution	O
containing	O
10	O
mg	O
/	O
mL	O
DEN	O
in	O
PBS	O
:	O
80	O
mg	O
/	O
kg	O
).	O

Mice	B-OG
were	O
sacrificed	O
at	O
36	O
weeks	O
after	O
DEN	O
injection	O
;	O
liver	O
was	O
assessed	O
for	O
macroscopic	O
tumour	B-DS
number	O
and	O
size	O
,	O
and	O
normal	O
liver	O
and	O
tumour	B-DS
samples	O
were	O
placed	O
into	O
RNA	O
later	O
,	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
or	O
fixed	O
in	O
neutral	O
buffered	O
formalin	O
overnight	O
at	O
4	O
°	O
C	O
for	O
the	O
assessment	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
.	O

Rapid	O
Apc	B-GP
inactivation	O
in	O
Apcfl	O
/	O
fl	O
mice	B-OG

To	O
investigate	O
the	O
phenotype	O
of	O
conditional	O
deletion	O
of	O
Apc	B-GP
,	O
AhCre	O
+	O
Apcfl	O
/	O
fl	O
and	O
AhCre	O
+	O
Apc	B-GP
+/+	O
progeny	O
were	O
used	O
as	O
previously	O
described	O
.	O
29	O
Mice	B-OG
were	O
given	O
daily	O
intraperitoneal	O
injections	O
of	O
β	O
-	O
napthoflavone	O
(	O
80	O
mg	O
/	O
kg	O
)	O
as	O
previously	O
reported	O
.	O
30	O
After	O
4	O
days	O
,	O
mice	B-OG
were	O
killed	O
and	O
liver	O
removed	O
,	O
weighed	O
and	O
placed	O
into	O
RNA	O
later	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
Missouri	O
,	O
USA	O
)	O
or	O
fixed	O
in	O
formalin	O
.	O

For	O
BrdU	O
labelling	O
,	O
mice	B-OG
were	O
injected	O
with	O
0	O
.	O
25	O
mL	O
of	O
BrdU	O
(	O
GE	O
Healthcare	O
,	O
Amersham	O
,	O
UK	O
),	O
2	O
hours	O
prior	O
to	O
sampling	O
,	O
and	O
staining	O
was	O
performed	O
using	O
an	O
anti	O
-	O
BrdU	O
antibody	B-GP
conjugate	O
(#	O
347580	O
,	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
California	O
,	O
USA	O
;	O
1	O
:	O
150	O
).	O

Staining	O
for	O
mouse	B-OG
β	B-GP
-	I-GP
catenin	I-GP
was	O
performed	O
on	O
sections	O
from	O
tissue	O
samples	O
fixed	O
at	O
4	O
°	O
C	O
for	O
<	O
24	O
hours	O
in	O
10	O
%	O
formalin	O
prior	O
to	O
processing	O
using	O
the	O
antibody	B-GP
(#	O
610154	O
,	O
BD	O
Biosciences	O
;	O
1	O
:	O
50	O
).	O

T	O
-	O
UCR	O
expression	O
profiling	O
in	O
mice	B-OG

RNA	O
from	O
the	O
liver	O
of	O
Apcfl	O
/	O
fl	O
(	O
n	O
:	O
3	O
),	O
Apc	B-GP
+/+	O
(	O
n	O
:	O
3	O
)	O
and	O
DEN	O
-	O
treated	O
mice	B-OG
(	O
n	O
:	O
3	O
)	O
were	O
used	O
.	O

mRNA	O
was	O
purified	O
from	O
total	O
RNA	O
after	O
removal	O
of	O
rRNA	O
(	O
mRNA	O
-	O
ONLY	O
Eukaryotic	O
mRNA	O
Isolation	O
Kit	O
,	O
Epicentre	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
USA	O
).	O

Then	O
,	O
each	O
sample	O
was	O
amplified	O
and	O
transcribed	O
into	O
fluorescent	O
cRNA	O
along	O
the	O
entire	O
length	O
of	O
the	O
transcripts	O
without	O
3	O
′	O
bias	O
,	O
using	O
a	O
random	O
priming	O
method	O
.	O

The	O
labelled	O
cRNAs	O
were	O
hybridised	O
onto	O
the	O
mouse	B-OG
LncRNA	O
Array	O
V	O
.	O
2	O
.	O
0	O
(	O
Arraystar	O
,	O
Rockville	O
,	O
Maryland	O
,	O
USA	O
),	O
which	O
also	O
included	O
probes	O
for	O
protein	O
-	O
coding	O
RNAs	O
.	O

The	O
arrays	O
were	O
scanned	O
by	O
the	O
Agilent	O
Scanner	O
G2505C	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
California	O
,	O
USA	O
).	O

Agilent	O
Feature	O
Extraction	O
software	O
(	O
V	O
.	O
11	O
.	O
0	O
.	O
1	O
.	O
1	O
)	O
was	O
used	O
to	O
analyse	O
the	O
acquired	O
array	O
images	O
.	O

Quantile	O
normalisation	O
and	O
subsequent	O
data	O
processing	O
were	O
performed	O
using	O
the	O
GeneSpring	O
GX	O
V	O
.	O
11	O
.	O
5	O
.	O
1	O
software	O
package	O
(	O
Agilent	O
Technologies	O
).	O

After	O
quantile	O
normalisation	O
of	O
the	O
raw	O
data	O
,	O
differentially	O
expressed	O
LncRNAs	O
with	O
statistical	O
significance	O
between	O
groups	O
(	O
Apcfl	O
/	O
fl	O
vs	O
Apc	B-GP
+/+;	O
Apcfl	O
/	O
fl	O
vs	O
DEN	O
-	O
HCC	B-DS
)	O
were	O
identified	O
through	O
volcano	O
plot	O
filtering	O
,	O
with	O
a	O
threshold	O
fold	O
change	O
≥	O
2	O
.	O
0	O
and	O
p	O
≤	O
0	O
.	O
05	O
.	O

Human	B-OG
tissues	O

The	O
human	B-OG
CCA	B-DS
tissues	O
were	O
collected	O
under	O
approval	O
of	O
the	O
Ethical	O
Committee	O
for	O
Clinical	O
Research	O
of	O
Padua	O
and	O
the	O
University	O
of	O
Edinburgh	O
ethics	O
committee	O
.	O

Healthy	O
liver	O
was	O
provided	O
by	O
the	O
NHS	O
Scotland	O
Research	O
(	O
NRS	O
)	O
BioResource	O
,	O
NHS	O
Lothian	O
.	O

All	O
tissues	O
were	O
collected	O
with	O
informed	O
consent	O
.	O

HCC	B-DS
tissues	O
were	O
provided	O
by	O
the	O
University	O
Hospital	O
Basel	O
and	O
University	O
of	O
Ferrara	O
after	O
appropriate	O
ethical	O
approval	O
.	O

For	O
the	O
CCA	B-DS
tissue	O
microarray	O
(	O
TMA	O
),	O
a	O
retrospective	O
series	O
(	O
1990	O
–	O
2011	O
)	O
of	O
102	O
surgically	O
resected	O
primary	O
biliary	B-DS
cancers	I-DS
,	O
including	O
85	O
CCA	B-DS
and	O
17	O
gall	B-DS
bladder	I-DS
carcinoma	I-DS
specimens	O
,	O
were	O
retrieved	O
from	O
the	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
archives	O
of	O
the	O
Department	O
of	O
Pathology	O
and	O
Diagnostics	O
and	O
the	O
ARC	O
-	O
NET	O
biobank	O
of	O
the	O
University	O
and	O
Hospital	O
Trust	O
of	O
Verona	O
after	O
appropriate	O
ethical	O
approval	O
.	O

CCAs	O
were	O
classified	O
according	O
to	O
WHO	O
2010	O
as	O
intrahepatic	B-DS
cholangiocarcinoma	I-DS
(	O
ICC	B-DS
,	O
n	O
=	O
54	O
)	O
and	O
extrahepatic	B-DS
cholangiocarcinoma	I-DS
(	O
ECC	B-DS
;	O
n	O
=	O
31	O
).	O

Five	O
1	O
mm	O
core	O
TMAs	O
were	O
assembled	O
.	O

Additional	O
14	O
non	O
-	O
neoplastic	O
controls	O
were	O
included	O
in	O
the	O
TMAs	O
.	O

Three	O
tissue	O
cores	O
per	O
case	O
were	O
analysed	O
.	O

Statistical	O
analysis	O

Statistical	O
analyses	O
were	O
performed	O
by	O
GraphPad	O
Prism	O
6	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
USA	O
).	O

Results	O
are	O
expressed	O
as	O
mean	O
±	O
SD	O
,	O
unless	O
indicated	O
otherwise	O
.	O

Groups	O
that	O
were	O
normally	O
distributed	O
were	O
compared	O
with	O
either	O
a	O
two	O
-	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
for	O
analysis	O
of	O
two	O
groups	O
)	O
or	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
to	O
compare	O
multiple	O
groups	O
.	O

Non	O
-	O
parametric	O
data	O
were	O
analysed	O
using	O
a	O
Wilcoxon	O
-	O
Mann	O
-	O
Whitney	O
U	O
test	O
when	O
comparing	O
two	O
groups	O
.	O

Significance	O
was	O
accepted	O
when	O
p	O
<	O
0	O
.	O
05	O
.	O
*	O
p	O
:	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**	O
p	O
:	O
0	O
.	O
009	O
–	O
0	O
.	O
001	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Additional	O
methods	O
can	O
be	O
found	O
in	O
the	O
online	O
supplementary	O
information	O
,	O
along	O
with	O
the	O
primer	O
sequences	O
(	O
see	O
online	O
supplementary	O
table	O
S1	O
).	O


Results	O

T	O
-	O
UCR	O
profiling	O
in	O
HCC	B-DS
mouse	B-OG
models	O

Hypomorphic	O
Apc	B-GP
mice	B-OG
(	O
Apcfl	O
/	O
fl	O
)	O
were	O
previously	O
shown	O
to	O
develop	O
HCC	B-DS
with	O
activation	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
(	O
nuclear	O
localisation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
and	O
activation	O
of	O
Wnt	B-GP
-	O
related	O
genes	O
).	O
26	O
To	O
assess	O
T	O
-	O
UCRs	O
downstream	O
of	O
the	O
Wnt	B-GP
pathway	O
,	O
we	O
profiled	O
ncRNA	O
expression	O
by	O
microarray	O
in	O
the	O
liver	O
of	O
Apcfl	O
/	O
fl	O
and	O
control	O
Apc	B-GP
+/+	O
mice	B-OG
.	O

Twenty	O
-	O
two	O
T	O
-	O
UCRs	O
were	O
aberrantly	O
expressed	O
(	O
figure	O
1A	O
,	O
see	O
online	O
supplementary	O
table	O
S2	O
),	O
with	O
four	O
upregulated	O
and	O
eighteen	O
downregulated	O
,	O
greater	O
than	O
twofold	O
,	O
in	O
tumour	B-DS
tissues	O
from	O
APCfl	O
/	O
fl	O
compared	O
with	O
normal	O
liver	O
from	O
Apc	B-GP
+/+.	O

To	O
verify	O
if	O
these	O
T	O
-	O
UCRs	O
were	O
specifically	O
altered	O
by	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
or	O
just	O
affected	O
by	O
the	O
malignant	O
transformation	O
,	O
we	O
profiled	O
T	O
-	O
UCR	O
expression	O
in	O
the	O
livers	O
of	O
mice	B-OG
treated	O
with	O
DEN	O
,	O
which	O
developed	O
a	O
median	O
of	O
17	O
(	O
range	O
:	O
13	O
–	O
36	O
)	O
tumours	B-DS
per	O
liver	O
with	O
no	O
nuclear	O
activation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
(	O
see	O
online	O
supplementary	O
figure	O
S1	O
).	O

Interestingly	O
,	O
we	O
found	O
that	O
four	O
T	O
-	O
UCRs	O
could	O
further	O
differentiate	O
Apcfl	O
/	O
fl	O
-	O
HCC	B-DS
from	O
DEN	O
-	O
induced	O
HCC	B-DS
(	O
figure	O
1A	O
,	O
see	O
online	O
supplementary	O
table	O
S3	O
).	O

Expression	O
of	O
uc	O
.	O
158	O
−,	O
uc	O
.	O
455	O
+,	O
uc	O
.	O
196	O
+	O
and	O
uc	O
.	O
82	O
−	O
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
in	O
the	O
liver	O
tissues	O
of	O
a	O
second	O
series	O
of	O
Apcfl	O
/	O
fl	O
and	O
control	O
Apc	B-GP
+/+	O
mice	B-OG
(	O
figure	O
1B	O
).	O
uc	O
.	O
158	O
−	O
and	O
uc	O
.	O
455	O
+	O
were	O
confirmed	O
to	O
be	O
significantly	O
upregulated	O
and	O
downregulated	O
,	O
respectively	O
,	O
in	O
Wnt	B-GP
-	O
dependent	O
HCC	B-DS
.	O
uc	O
.	O
158	O
−	O
is	O
an	O
intergenic	O
224	O
nt	O
long	O
UCR	O
located	O
on	O
chromosome	O
13	O
in	O
the	O
mouse	B-OG
and	O
on	O
chromosome	O
5	O
in	O
the	O
human	B-OG
genome	O
.	O
uc	O
.	O
455	O
+	O
is	O
a	O
245	O
nt	O
long	O
UCR	O
located	O
on	O
chromosome	O
2	O
in	O
the	O
mouse	B-OG
and	O
on	O
chromosome	O
20	O
in	O
the	O
human	B-OG
genome	O
,	O
where	O
it	O
overlaps	O
in	O
antisense	O
the	O
RNA	B-GP
-	I-GP
binding	I-GP
protein	I-GP
motif	I-GP
39	I-GP
(	O
RBPM39	B-GP
)	O
gene	O
.	O

Given	O
the	O
fact	O
that	O
uc	O
.	O
158	O
−	O
does	O
not	O
overlap	O
protein	O
-	O
coding	O
genes	O
,	O
and	O
that	O
intergenic	O
lncRNAs	O
have	O
been	O
shown	O
to	O
be	O
more	O
stable	O
,	O
31	O
we	O
focused	O
on	O
uc	O
.	O
158	O
−	O
for	O
further	O
studies	O
.	O

Transcribed	O
-	O
ultraconserved	O
regions	O
(	O
T	O
-	O
UCR	O
)	O
profiling	O
in	O
an	O
Apc	B-GP
hypomorphic	O
hepatocarcinoma	B-DS
(	O
HCC	B-DS
)	O
mouse	B-OG
model	O
.	O

(	O
A	O
)	O
T	O
-	O
UCRs	O
aberrantly	O
expressed	O
in	O
Apcfl	O
/	O
fl	O
(	O
n	O
:	O
3	O
)	O
versus	O
control	O
Apc	B-GP
+/+	O
(	O
n	O
:	O
3	O
)	O
mice	B-OG
livers	O
.	O

Fold	O
change	O
has	O
been	O
plotted	O
against	O
p	O
values	O
,	O
with	O
lowest	O
p	O
values	O
being	O
on	O
the	O
top	O
of	O
the	O
y	O
-	O
axis	O
.	O

T	O
-	O
UCRs	O
highlighted	O
in	O
red	O
are	O
those	O
that	O
were	O
common	O
across	O
the	O
two	O
profiling	O
comparing	O
Apcfl	O
/	O
fl	O
versus	O
Apc	B-GP
+/+	O
and	O
comparing	O
Apcfl	O
/	O
fl	O
versus	O
diethylnitrosamine	O
(	O
DEN	O
)-	O
induced	O
HCC	B-DS
(	O
n	O
:	O
3	O
).	O

(	O
B	O
)	O
Validation	O
of	O
T	O
-	O
UCR	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
four	O
samples	O
.	O

Uc	O
.	O
158	O
−	O
expression	O
is	O
downstream	O
of	O
Wnt	B-GP
signalling	O
in	O
human	B-OG
liver	B-DS
cancer	I-DS
cells	O

To	O
understand	O
the	O
human	B-OG
relevance	O
of	O
previous	O
findings	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
in	O
human	B-OG
malignant	O
hepatocytes	O
.	O

HepG2	O
cells	O
are	O
known	O
to	O
harbour	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
β	B-GP
-	I-GP
catenin	I-GP
gene	O
(	O
CTNNB1	B-GP
),	O
while	O
Huh	O
-	O
7	O
cells	O
are	O
known	O
to	O
be	O
wild	O
type	O
(	O
WT	O
)	O
for	O
CTNNB1	B-GP
and	O
other	O
genes	O
of	O
the	O
Wnt	B-GP
pathway	O
.	O
6	O
The	O
Wnt	B-GP
pathway	O
is	O
activated	O
in	O
HepG2	O
cell	O
lines	O
,	O
but	O
not	O
in	O
Huh	O
-	O
7	O
,	O
in	O
line	O
with	O
the	O
mutational	O
status	O
of	O
these	O
cells	O
(	O
see	O
online	O
supplementary	O
table	O
S4	O
and	O
figure	O
S2A	O
,	O
B	O
).	O

Global	O
lncRNA	O
expression	O
analysis	O
revealed	O
that	O
uc	O
.	O
158	O
−	O
is	O
increased	O
in	O
malignant	O
hepatocytes	O
in	O
comparison	O
with	O
normal	O
human	B-OG
hepatocytes	O
and	O
that	O
overexpression	O
is	O
greater	O
in	O
HepG2	O
than	O
in	O
Huh	O
-	O
7	O
(	O
see	O
online	O
supplementary	O
figure	O
S2C	O
).	O

We	O
then	O
extended	O
our	O
studies	O
to	O
a	O
panel	O
of	O
malignant	O
hepatocytes	O
.	O

Immunofluorescence	O
showed	O
that	O
β	B-GP
-	I-GP
catenin	I-GP
localises	O
in	O
the	O
nuclei	O
of	O
HepG2	O
cells	O
and	O
Hep	O
-	O
3B	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
(	O
figure	O
2A	O
),	O
as	O
previously	O
described	O
.	O
32	O
Interestingly	O
,	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
reflects	O
this	O
finding	O
,	O
with	O
the	O
highest	O
expression	O
being	O
in	O
HepG2	O
(	O
figure	O
2B	O
).	O

PLC	O
/	O
PRF	O
-	O
5	O
cells	O
had	O
a	O
very	O
low	O
expression	O
of	O
uc	O
.	O
158	O
−	O
and	O
did	O
not	O
show	O
localisation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
despite	O
their	O
mutation	O
in	O
AXIN1	B-GP
33	O
(	O
figure	O
2A	O
,	O
B	O
).	O

To	O
further	O
study	O
this	O
finding	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
in	O
the	O
liver	O
of	O
mice	B-OG
genetically	O
engineered	O
to	O
harbour	O
deletion	O
of	O
Axin1	B-GP
.	O

These	O
animals	B-OG
(	O
Axin1fl	O
/	O
fl	O
/	O
Cre	B-GP
)	O
were	O
shown	O
to	O
develop	O
microscopic	O
foci	O
of	O
HCC	B-DS
in	O
the	O
absence	O
of	O
nuclear	O
localisation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
.	O
28	O
In	O
line	O
with	O
previous	O
findings	O
,	O
we	O
did	O
not	O
detect	O
any	O
change	O
in	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
in	O
the	O
liver	O
of	O
Axin1fl	O
/	O
fl	O
/	O
Cre	B-GP
in	O
comparison	O
with	O
WT	O
mice	B-OG
(	O
figure	O
2C	O
).	O

uc	O
.	O
158	O
−	O
expression	O
is	O
dependent	O
on	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
human	B-OG
malignant	O
hepatocytes	O
.	O

(	O
A	O
)	O
Immunofluorescence	O
was	O
performed	O
for	O
β	B-GP
-	I-GP
catenin	I-GP
(	O
CTNNB1	B-GP
)	O
and	O
Hoechst	O
in	O
a	O
panel	O
of	O
malignant	O
hepatocytes	O
.	O

Scale	O
bar	O
:	O
50	O
μm	O
(	O
B	O
)	O
Expression	O
of	O
uc	O
.	O
158	O
−	O
was	O
assessed	O
in	O
the	O
same	O
panel	O
of	O
malignant	O
hepatocytes	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
independent	O
samples	O
.	O

(	O
C	O
)	O
uc	O
.	O
158	O
−	O
expression	O
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
in	O
the	O
liver	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
Axin1fl	O
/	O
fl	O
/	O
Cre	B-GP
mice	B-OG
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
six	O
samples	O
.	O
p	O
>	O
0	O
.	O
05	O
.	O

(	O
D	O
)	O
Huh	O
-	O
7	O
cells	O
were	O
treated	O
with	O
25	O
mM	O
LiCl	O
or	O
diluent	O
control	O
for	O
24	O
hours	O
and	O
cells	O
collected	O
to	O
assess	O
induction	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
protein	O
expression	O
by	O
western	O
blotting	O
,	O
induction	O
of	O
nuclear	O
localisation	O
by	O
immunofluorescence	O
and	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
experiments	O
.	O

(	O
E	O
)	O
HepG2	O
cells	O
were	O
transfected	O
with	O
siRNA	O
against	O
CTNNB1	B-GP
(	O
siCTNNB1	O
)	O
or	O
siRNA	O
CTRL	O
(	O
50	O
nM	O
)	O
for	O
48	O
hours	O
,	O
and	O
cells	O
collected	O
to	O
assess	O
reduction	O
in	O
expression	O
of	O
CTNNB1	B-GP
mRNA	O
,	O
protein	O
expression	O
and	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
experiments	O
.	O

(	O
F	O
)	O
HepG2	O
cells	O
were	O
treated	O
with	O
50	O
μM	O
ICG	O
-	O
001	O
for	O
24	O
hours	O
,	O
and	O
cells	O
collected	O
to	O
assess	O
downregulation	O
of	O
drug	O
-	O
target	O
mRNAs	O
and	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
experiments	O
.	O

To	O
further	O
validate	O
the	O
dependency	O
of	O
uc	O
.	O
158	O
−	O
on	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
,	O
we	O
assessed	O
its	O
expression	O
after	O
modulation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
in	O
vitro	O
.	O

Treatment	O
of	O
Huh	O
-	O
7	O
cells	O
with	O
LiCl	O
induced	O
activation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
and	O
an	O
increase	O
in	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
(	O
figure	O
2D	O
).	O

Inhibition	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
by	O
siRNA	O
or	O
by	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
inhibitor	O
ICG	O
-	O
001	O
induced	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
in	O
HepG2	O
cells	O
(	O
figure	O
2E	O
,	O
F	O
).	O

Uc	O
.	O
158	O
−	O
expression	O
in	O
human	B-OG
HCC	B-DS
tissues	O

We	O
have	O
previously	O
shown	O
that	O
T	O
-	O
UCRs	O
are	O
transcribed	O
as	O
independent	O
transcripts	O
which	O
are	O
longer	O
than	O
the	O
UCRs	O
described	O
by	O
Bejerano	O
.	O
25	O
To	O
characterise	O
the	O
5	O
′-	O
end	O
of	O
the	O
transcript	O
including	O
uc	O
.	O
158	O
−,	O
we	O
performed	O
a	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
).	O

We	O
have	O
shown	O
that	O
uc	O
.	O
158	O
−	O
is	O
transcribed	O
in	O
antisense	O
and	O
that	O
the	O
5	O
-	O
end	O
is	O
characterised	O
by	O
additional	O
306	O
nucleotides	O
upstream	O
of	O
the	O
known	O
uc	O
.	O
158	O
−	O
(	O
see	O
online	O
supplementary	O
figure	O
S3	O
).	O

To	O
confirm	O
the	O
transcript	O
is	O
transcribed	O
in	O
antisense	O
,	O
we	O
performed	O
in	O
situ	O
hybridisation	O
in	O
FFPE	O
human	B-OG
liver	O
tissues	O
.	O

We	O
used	O
three	O
different	O
probes	O
:	O
S1	O
which	O
recognised	O
the	O
sense	O
uc	O
.	O
158	O
+	O
and	O
AS1	O
and	O
AS3	O
which	O
both	O
could	O
detect	O
the	O
antisense	O
uc	O
.	O
158	O
−.	O

In	O
line	O
with	O
our	O
RACE	O
experiments	O
,	O
S1	O
did	O
not	O
show	O
any	O
signal	O
,	O
confirming	O
that	O
uc	O
.	O
158	O
−	O
is	O
transcribed	O
in	O
antisense	O
(	O
see	O
online	O
supplementary	O
figure	O
S3	O
).	O

We	O
next	O
analysed	O
a	O
series	O
of	O
human	B-OG
FFPE	O
liver	O
tissues	O
.	O

Cirrhotic	O
tissues	O
were	O
negative	O
for	O
uc	O
.	O
158	O
−	O
expression	O
,	O
while	O
HCC	B-DS
tissues	O
were	O
positive	O
.	O

However	O
,	O
it	O
is	O
of	O
note	O
that	O
HCC	B-DS
with	O
negative	O
or	O
membranous	O
expression	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
had	O
a	O
weak	O
/	O
moderate	O
cytoplasmic	O
expression	O
,	O
while	O
liver	B-DS
tumours	I-DS
with	O
nuclear	O
β	B-GP
-	I-GP
catenin	I-GP
showed	O
the	O
most	O
intense	O
signal	O
(	O
figure	O
3A	O
,	O
see	O
online	O
supplementary	O
table	O
S5	O
).	O

Next	O
,	O
we	O
studied	O
a	O
second	O
cohort	O
of	O
human	B-OG
frozen	O
HCCs	B-DS
where	O
CTNNB1	B-GP
,	O
APC	B-GP
and	O
AXIN1	B-GP
genes	O
were	O
analysed	O
by	O
sequencing	O
(	O
as	O
previously	O
described34	O
).	O

The	O
median	O
expression	O
of	O
uc	O
.	O
158	O
−	O
was	O
significantly	O
higher	O
in	O
the	O
mutated	O
group	O
(	O
which	O
included	O
six	O
CTNNB1	B-GP
-	O
mutated	O
and	O
one	O
APC	B-GP
-	O
mutated	O
HCC	B-DS
)	O
than	O
in	O
WT	O
controls	O
(	O
figure	O
3B	O
).	O

However	O
,	O
isolated	O
WT	O
HCCs	B-DS
showed	O
an	O
increased	O
expression	O
of	O
uc	O
.	O
158	O
−,	O
suggesting	O
that	O
in	O
rare	O
cases	O
the	O
source	O
of	O
uc	O
.	O
158	O
−	O
may	O
be	O
alternative	O
to	O
the	O
mutations	O
studied	O
.	O

Indeed	O
,	O
hepatitis	B-DS
liver	O
tissues	O
showed	O
negative	O
non	O
-	O
neoplastic	O
hepatocytes	O
and	O
positive	O
lymphocytes	O
(	O
see	O
online	O
supplementary	O
figure	O
S4A	O
),	O
suggesting	O
that	O
the	O
stroma	O
may	O
represent	O
a	O
source	O
of	O
uc	O
.	O
158	O
−.	O

To	O
understand	O
if	O
uc	O
.	O
158	O
−	O
is	O
specific	O
to	O
malignant	O
cells	O
or	O
can	O
be	O
expressed	O
also	O
in	O
non	O
-	O
tumour	B-DS
hepatocytes	O
,	O
we	O
looked	O
at	O
uc	O
.	O
158	O
−	O
expression	O
in	O
the	O
liver	O
of	O
a	O
mouse	B-OG
model	O
with	O
conditional	O
Apc	B-GP
deletion	O
(	O
AhCre	O
+	O
Apcfl	O
/	O
fl	O
),	O
which	O
presents	O
an	O
increase	O
in	O
liver	O
weight	O
and	O
proliferation	O
,	O
but	O
not	O
tumours	B-DS
.	O

Indeed	O
,	O
we	O
noticed	O
that	O
uc	O
.	O
158	O
−	O
expression	O
was	O
not	O
changed	O
following	O
activation	O
of	O
the	O
Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
pathway	O
in	O
absence	O
of	O
cancer	B-DS
(	O
figure	O
4	O
).	O

uc	O
.	O
158	O
−	O
expression	O
in	O
human	B-OG
hepatocarcinoma	B-DS
(	O
HCC	B-DS
)	O
tissues	O
.	O

(	O
A	O
)	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
human	B-OG
liver	O
tissues	O
have	O
been	O
analysed	O
for	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
RNA	O
in	O
situ	O
hybridisation	O
and	O
for	O
CTNNB1	B-GP
protein	O
expression	O
by	O
immunohistochemistry	O
.	O

Scale	O
bars	O
:	O
200	O
μM	O
for	O
the	O
top	O
and	O
bottom	O
line	O
,	O
50	O
μM	O
for	O
the	O
second	O
line	O
.	O

(	O
B	O
)	O
DNA	O
and	O
RNA	O
were	O
extracted	O
from	O
15	O
frozen	O
HCC	B-DS
tissues	O
and	O
used	O
for	O
uc	O
.	O
158	O
−	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
and	O
sequencing	O
analysis	O
for	O
APC	B-GP
,	O
AXIN1	B-GP
and	O
exon	O
3	O
of	O
CTNNB1	B-GP
.	O

The	O
circled	O
orange	O
dot	O
represents	O
a	O
case	O
with	O
mutation	O
of	O
APC	B-GP
.	O

Bars	O
represent	O
median	O
with	O
IQR	O
.	O

Mann	O
-	O
Whitney	O
test	O
,	O
exact	O
two	O
-	O
tailed	O
p	O
value	O
:	O
0	O
.	O
04	O
.	O

Apc	B-GP
deletion	O
does	O
not	O
induce	O
uc	O
.	O
158	O
−	O
in	O
the	O
absence	O
of	O
tumour	B-DS
.	O

Conditional	O
Apc	B-GP
deletion	O
induced	O
by	O
β	O
-	O
napthoflavone	O
injection	O
in	O
AhCre	O
+	O
Apc	B-GP
+/+	O
and	O
AhCre	O
+	O
Apcfl	O
/	O
fl	O
mice	B-OG
on	O
day	O
1	O
.	O

Mice	B-OG
(	O
n	O
=	O
3	O
for	O
each	O
group	O
)	O
were	O
euthanised	O
on	O
day	O
4	O
,	O
and	O
liver	O
weighed	O
and	O
processed	O
for	O
downstream	O
analyses	O
.	O

(	O
A	O
)	O
IHC	O
analysis	O
for	O
CTNNB1	B-GP
and	O
BrDU	O
.	O

Scale	O
bar	O
:	O
10	O
μM	O
(	O
B	O
)	O
Liver	O
weight	O
is	O
expressed	O
as	O
percentage	O
of	O
the	O
whole	O
body	O
weight	O
(	O
median	O
and	O
range	O
).	O

(	O
C	O
)	O
Expression	O
of	O
uc	O
.	O
158	O
−	O
(	O
median	O
and	O
range	O
).	O

Uc	O
.	O
158	O
−	O
in	O
CCA	B-DS

Recent	O
evidence	O
has	O
shown	O
that	O
CCA	B-DS
,	O
another	O
form	O
of	O
primary	B-DS
liver	I-DS
cancer	I-DS
,	O
is	O
dependent	O
on	O
the	O
Wnt	B-GP
pathway	O
despite	O
the	O
lack	O
of	O
CTNNB1	B-GP
mutations	O
in	O
malignant	O
cholangiocytes	O
.	O
27	O
35	O
–	O
37	O
In	O
order	O
to	O
understand	O
if	O
our	O
findings	O
were	O
disease	O
-	O
specific	O
or	O
could	O
be	O
extended	O
also	O
to	O
CCA	B-DS
,	O
we	O
looked	O
at	O
uc	O
.	O
158	O
−	O
expression	O
in	O
an	O
initial	O
cohort	O
of	O
British	O
human	B-OG
intrahepatic	B-DS
CCAs	I-DS
(	O
ICC	B-DS
)	O
and	O
found	O
that	O
uc	O
.	O
158	O
−	O
was	O
significantly	O
overexpressed	O
in	O
tumour	B-DS
tissues	O
compared	O
with	O
healthy	O
livers	O
(	O
figure	O
5A	O
).	O

Interestingly	O
,	O
uc	O
.	O
158	O
−	O
was	O
increased	O
in	O
CCA	B-DS
compared	O
with	O
normal	O
tissues	O
in	O
all	O
four	O
cases	O
for	O
which	O
matched	O
adjacent	O
tissues	O
were	O
available	O
(	O
figure	O
5B	O
).	O

These	O
data	O
were	O
confirmed	O
in	O
another	O
series	O
of	O
Italian	O
CCA	B-DS
by	O
in	O
situ	O
hybridisation	O
.	O

We	O
studied	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
using	O
a	O
TMA	O
including	O
54	O
ICC	B-DS
,	O
31	O
extrahepatic	B-DS
CCA	I-DS
(	O
ECC	B-DS
)	O
and	O
17	O
gall	B-DS
bladder	I-DS
cancers	I-DS
(	O
GBC	B-DS
),	O
along	O
with	O
additional	O
8	O
normal	O
biliary	O
ducts	O
and	O
liver	O
parenchyma	O
and	O
6	O
liver	O
tissues	O
adjacent	O
to	O
CCA	B-DS
(	O
see	O
online	O
supplementary	O
table	O
S6	O
).	O

Normal	O
biliary	O
epithelia	O
and	O
liver	O
parenchyma	O
were	O
always	O
uc	O
.	O
158	O
−	O
negative	O
.	O

High	O
uc	O
.	O
158	O
−	O
expression	O
(++/+++)	O
was	O
detected	O
in	O
74	O
%	O
of	O
ICC	B-DS
,	O
58	O
%	O
of	O
ECC	B-DS
and	O
24	O
%	O
of	O
GBC	B-DS
(	O
figure	O
5C	O
,	O
see	O
online	O
supplementary	O
table	O
S6	O
).	O

Adequate	O
paired	O
tumoural	O
and	O
adjacent	O
non	O
-	O
tumoural	O
tissues	O
for	O
analysis	O
were	O
available	O
from	O
six	O
cases	O
,	O
and	O
in	O
all	O
of	O
them	O
uc	O
.	O
158	O
−	O
was	O
overexpressed	O
.	O

Interestingly	O
,	O
the	O
perilesional	O
adjacent	O
liver	O
was	O
rarely	O
negative	O
,	O
and	O
most	O
of	O
them	O
showed	O
weak	O
/	O
moderate	O
positivity	O
,	O
suggesting	O
that	O
uc	O
.	O
158	O
−	O
may	O
be	O
involved	O
in	O
the	O
carcinogenic	O
process	O
(	O
see	O
online	O
supplementary	O
figure	O
S5	O
).	O

Stromal	O
cells	O
were	O
strongly	O
positive	O
(	O
see	O
online	O
supplementary	O
figure	O
S4B	O
),	O
in	O
accordance	O
with	O
data	O
by	O
Boulter	O
et	O
al	O
27	O
showing	O
that	O
the	O
stroma	O
is	O
one	O
of	O
the	O
sources	O
of	O
Wnt	B-GP
in	O
CCA	B-DS
.	O

To	O
further	O
investigate	O
these	O
findings	O
,	O
we	O
studied	O
a	O
rat	B-OG
model	O
of	O
thiocetamide	O
(	O
TAA	O
)-	O
induced	O
CCA	B-DS
,	O
which	O
appropriately	O
models	O
ICC	B-DS
on	O
a	O
background	O
of	O
inflammation	O
and	O
activation	O
of	O
β	B-GP
-	I-GP
catenin	I-GP
,	O
as	O
previously	O
shown	O
.	O
27	O
uc	O
.	O
158	O
−	O
expression	O
was	O
increased	O
in	O
tumour	B-DS
tissues	O
compared	O
with	O
control	O
livers	O
,	O
confirming	O
that	O
uc	O
.	O
158	O
−	O
deregulation	O
is	O
conserved	O
across	O
species	O
along	O
with	O
the	O
sequence	O
(	O
figure	O
5D	O
).	O

To	O
further	O
prove	O
the	O
dependency	O
on	O
the	O
Wnt	B-GP
pathway	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
uc	O
.	O
158	O
−	O
after	O
treatment	O
with	O
two	O
different	O
Wnt	B-GP
inhibitors	O
.	O

ICG	O
-	O
001	O
reduced	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
52	O
%,	O
while	O
C	O
-	O
59	O
decreased	O
uc	O
.	O
158	O
−	O
expression	O
to	O
almost	O
undetectable	O
levels	O
in	O
rat	B-OG
CCA	B-DS
(	O
figure	O
5E	O
).	O

uc	O
.	O
158	O
−	O
expression	O
in	O
cholangiocarcinoma	B-DS
.	O

(	O
A	O
)	O
RNA	O
was	O
extracted	O
from	O
frozen	O
intrahepatic	B-DS
cholangiocarcinoma	I-DS
(	O
CCA	B-DS
)	O
(	O
n	O
:	O
5	O
)	O
and	O
normal	O
liver	O
(	O
n	O
:	O
8	O
)	O
tissues	O
and	O
assessed	O
for	O
uc	O
.	O
158	O
−	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SE	O
.	O

(	O
B	O
)	O
In	O
four	O
cases	O
,	O
CCA	B-DS
and	O
matched	O
adjacent	O
tissues	O
from	O
the	O
same	O
patients	O
were	O
available	O
.	O

Bars	O
represent	O
uc	O
.	O
158	O
−	O
expression	O
in	O
tumour	B-DS
tissue	O
relative	O
to	O
the	O
expression	O
in	O
the	O
adjacent	O
normal	O
tissue	O
.	O

Fold	O
change	O
tumour	B-DS
/	O
normal	O
(	O
T	O
/	O
N	O
)	O
is	O
reported	O
for	O
each	O
case	O
on	O
the	O
top	O
of	O
the	O
bars	O
.	O

(	O
C	O
)	O
A	O
tissue	O
microarray	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
human	B-OG
tissues	O
including	O
54	O
intrahepatic	B-DS
cholangiocarcinoma	I-DS
(	O
ICC	B-DS
),	O
31	O
extrahepatic	B-DS
cholangiocarcinoma	I-DS
(	O
ECC	B-DS
),	O
17	O
gallbladder	B-DS
cancers	I-DS
(	O
GBC	B-DS
)	O
and	O
8	O
normal	O
liver	O
tissues	O
was	O
assessed	O
for	O
expression	O
of	O
uc	O
.	O
158	O
−	O
by	O
RNA	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
with	O
AS3	O
probe	O
.	O

Pictures	O
of	O
representative	O
cases	O
are	O
shown	O
.	O

(	O
D	O
)	O
RNA	O
was	O
extracted	O
from	O
the	O
liver	O
of	O
thiocetamide	O
(	O
TAA	O
)-	O
treated	O
(	O
with	O
CCA	B-DS
)	O
or	O
vehicle	O
-	O
treated	O
(	O
normal	O
)	O
rats	B-OG
for	O
26	O
weeks	O
and	O
analysed	O
for	O
uc	O
.	O
158	O
−	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
samples	O
.	O

(	O
E	O
)	O
Rats	B-OG
with	O
TAA	O
-	O
induced	O
CCA	B-DS
were	O
treated	O
with	O
the	O
CTNNB1	B-GP
-	O
CTBP	B-GP
inhibitor	O
ICG	O
-	O
001	O
(	O
5	O
mg	O
/	O
kg	O
)	O
or	O
PORCN	B-GP
inhibitor	O
C	O
-	O
59	O
(	O
20	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
vehicle	O
by	O
intraperitoneal	O
injection	O
three	O
times	O
per	O
week	O
,	O
from	O
week	O
21	O
to	O
26	O
.	O

At	O
26	O
weeks	O
,	O
rats	B-OG
were	O
sacrificed	O
,	O
and	O
uc	O
.	O
158	O
−	O
expression	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
four	O
samples	O
.	O

Biological	O
relevance	O
of	O
uc	O
.	O
158	O
−	O

To	O
gain	O
insights	O
into	O
the	O
biological	O
relevance	O
of	O
uc	O
.	O
158	O
−,	O
we	O
studied	O
phenotypical	O
changes	O
induced	O
by	O
inhibition	O
of	O
uc	O
.	O
158	O
−	O
in	O
HepG2	O
cells	O
.	O

We	O
tested	O
four	O
different	O
locked	O
nucleic	O
acid	O
probes	O
(	O
GAPMER	O
,	O
GAP1	O
-	O
4	O
)	O
specifically	O
designed	O
to	O
interact	O
with	O
the	O
conserved	O
sequence	O
of	O
uc	O
.	O
158	O
−.	O

GAP1	O
and	O
GAP3	O
provided	O
the	O
best	O
inhibition	O
(	O
see	O
online	O
supplementary	O
figure	O
S6	O
)	O
and	O
therefore	O
were	O
selected	O
for	O
further	O
experiments	O
.	O

Cell	O
growth	O
was	O
reduced	O
by	O
60	O
%	O
and	O
70	O
%	O
at	O
72	O
hours	O
in	O
HepG2	O
cells	O
transfected	O
with	O
GAP1	O
and	O
GAP3	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
control	O
(	O
CTRL	O
)	O
probe	O
(	O
figure	O
6A	O
).	O

To	O
better	O
understand	O
the	O
mechanism	O
through	O
which	O
cell	O
viability	O
is	O
affected	O
,	O
we	O
ran	O
a	O
cell	O
cycle	O
analysis	O
after	O
transfection	O
,	O
and	O
noticed	O
that	O
there	O
were	O
no	O
changes	O
in	O
the	O
progression	O
through	O
the	O
cell	O
cycle	O
phases	O
,	O
but	O
for	O
an	O
increased	O
accumulation	O
of	O
cells	O
in	O
the	O
sub	O
-	O
GO	O
/	O
1	O
phase	O
(	O
potentially	O
apoptotic	O
)	O
in	O
cells	O
transfected	O
with	O
GAP1	O
and	O
GAP3	O
(	O
figure	O
6B	O
).	O

Indeed	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
activated	O
caspase	B-GP
3	I-GP
/	O
7	O
by	O
luminescence	O
(	O
figure	O
6C	O
)	O
with	O
no	O
increase	O
in	O
necrosis	O
(	O
see	O
online	O
supplementary	O
figure	O
S7	O
).	O

Increase	O
in	O
the	O
expression	O
of	O
caspases	B-GP
and	O
cleaved	O
poly	B-GP
ADP	I-GP
ribose	I-GP
polymerase	I-GP
(	O
PARP	B-GP
)	O
was	O
also	O
noted	O
after	O
uc	O
.	O
158	O
−	O
silencing	O
(	O
figure	O
6D	O
,	O
see	O
online	O
supplementary	O
figure	O
S8	O
).	O

uc	O
.	O
158	O
−	O
inhibition	O
reduces	O
cancer	B-DS
cell	O
growth	O
.	O

(	O
A	O
)	O
HepG2	O
cells	O
were	O
reverse	O
-	O
transfected	O
with	O
GAPMER	O
probes	O
anti	O
-	O
uc	O
.	O
158	O
−	O
GAP1	O
and	O
GAP3	O
or	O
control	O
-	O
scrambled	O
probe	O
(	O
CTRL	O
)	O
in	O
96	O
well	O
plates	O
,	O
and	O
cell	O
viability	O
assessed	O
by	O
CellTiter	O
-	O
Blue	O
after	O
72	O
hours	O
.	O

Non	O
-	O
transfected	O
(	O
untreated	O
)	O
cells	O
were	O
added	O
as	O
control	O
for	O
transfection	O
toxicity	O
.	O

Representative	O
pictures	O
and	O
quantification	O
of	O
seven	O
replicates	O
with	O
mean	O
±	O
SD	O
are	O
represented	O
.	O

Scale	O
bar	O
:	O
400	O
μM	O
.	O

(	O
B	O
)	O
HepG2	O
cells	O
were	O
transfected	O
,	O
and	O
analysis	O
of	O
cell	O
-	O
cycle	O
distribution	O
was	O
performed	O
by	O
flow	O
cytometry	O
.	O

Quantification	O
of	O
three	O
experiments	O
(	O
mean	O
±	O
SD	O
)	O
is	O
shown	O
on	O
the	O
left	O
.	O

The	O
representative	O
picture	O
on	O
the	O
right	O
shows	O
peaks	O
for	O
cells	O
transfected	O
with	O
CTRL	O
,	O
GAP1	O
and	O
GAP3	O
probes	O
.	O

In	O
the	O
red	O
square	O
,	O
representative	O
zoom	O
of	O
the	O
sub	O
-	O
G0	O
/	O
G1	O
peak	O
.	O

(	O
C	O
)	O
HepG2	O
cells	O
were	O
reverse	O
-	O
transfected	O
in	O
96	O
well	O
plates	O
,	O
and	O
activation	O
of	O
caspase	B-GP
3	I-GP
/	O
7	O
was	O
assessed	O
by	O
luminescence	O
assay	O
.	O

Staurosporine	O
was	O
added	O
as	O
positive	O
control	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
replicates	O
.	O

Asterisks	O
indicate	O
p	O
value	O
by	O
t	O
-	O
test	O
analysis	O
.	O

Analysis	O
of	O
variance	O
comparison	O
was	O
performed	O
comparing	O
all	O
the	O
groups	O
,	O
or	O
only	O
the	O
three	O
experimental	O
groups	O
(	O
CTRL	O
,	O
GAP1	O
,	O
GAP3	O
),	O
with	O
the	O
following	O
results	O
:	O
p	O
:	O
0	O
.	O
0004	O
and	O
p	O
:	O
0	O
.	O
0012	O
,	O
respectively	O
,	O
at	O
6	O
hours	O
;	O
p	O
<	O
0	O
.	O
0001	O
for	O
both	O
comparisons	O
at	O
24	O
hours	O
.	O

(	O
D	O
)	O
HepG2	O
cells	O
were	O
transfected	O
with	O
GAPMER	O
probe	O
anti	O
-	O
uc	O
.	O
158	O
−	O
GAP1	O
or	O
CTRL	O
-	O
scrambled	O
probe	O
and	O
then	O
fixed	O
in	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
.	O

Immunohistochemistry	O
was	O
then	O
performed	O
for	O
caspase	B-GP
3	I-GP
.	O

Representative	O
pictures	O
of	O
two	O
independent	O
experiments	O
are	O
shown	O
.	O

(	O
E	O
)	O
HepG2	O
cells	O
were	O
reverse	O
-	O
transfected	O
with	O
anti	O
-	O
uc	O
.	O
158	O
−	O
GAP1	O
and	O
GAP3	O
or	O
control	O
probe	O
in	O
100	O
mm	O
dishes	O
and	O
then	O
plated	O
in	O
ultra	O
low	O
attachment	O
(	O
ULA	O
)	O
96	O
-	O
well	O
plates	O
to	O
form	O
spheroids	O
.	O

Imaging	O
and	O
quantitation	O
were	O
performed	O
after	O
7	O
days	O
with	O
Celigo	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
six	O
replicates	O
.	O

(	O
F	O
)	O
Once	O
the	O
spheroids	O
were	O
formed	O
,	O
they	O
were	O
moved	O
to	O
flat	O
-	O
bottom	O
,	O
gelatin	O
-	O
coated	O
96	O
-	O
well	O
plates	O
,	O
and	O
migration	O
was	O
assessed	O
at	O
different	O
time	O
points	O
through	O
Celigo	O
.	O

Anchorage	O
-	O
independent	O
growth	O
was	O
assessed	O
by	O
tumour	B-DS
3D	O
spheroid	O
assay	O
.	O

The	O
volume	O
of	O
3D	O
spheroid	O
generated	O
from	O
HepG2	O
cells	O
transfected	O
with	O
GAP	O
1	O
and	O
GAP3	O
was	O
reduced	O
to	O
34	O
%	O
and	O
40	O
%,	O
respectively	O
,	O
in	O
comparison	O
with	O
spheroids	O
generated	O
from	O
cells	O
transfected	O
with	O
GAP	O
CTRL	O
(	O
figure	O
6E	O
).	O

In	O
addition	O
,	O
uc	O
.	O
158	O
−	O
silencing	O
reduced	O
tumour	B-DS
spheroid	O
-	O
based	O
migration	O
in	O
HepG2	O
cells	O
(	O
figure	O
6F	O
).	O

These	O
data	O
were	O
also	O
confirmed	O
in	O
CCA	B-DS
SW1	O
cells	O
whose	O
cell	O
viability	O
was	O
dependent	O
on	O
the	O
Wnt	B-GP
pathway	O
(	O
see	O
online	O
supplementary	O
figure	O
S9	O
).	O

Uc	O
.	O
158	O
−	O
acts	O
as	O
a	O
competing	O
endogenous	O
RNA	O

Recent	O
evidence	O
suggests	O
that	O
T	O
-	O
UCRs	O
may	O
act	O
as	O
endogenous	O
competing	O
RNAs	O
(	O
ceRNA	O
).	O
38	O
Thus	O
,	O
we	O
searched	O
for	O
potential	O
binding	O
sites	O
for	O
miRNAs	O
in	O
the	O
uc	O
.	O
158	O
−	O
conserved	O
sequence	O
.	O

We	O
shortlisted	O
those	O
miRNAs	O
which	O
are	O
conserved	O
across	O
mouse	B-OG
and	O
human	B-OG
and	O
show	O
a	O
binding	O
site	O
with	O
a	O
predicted	O
ddG	O
score	O
<−	O
10	O
(	O
see	O
online	O
supplementary	O
figure	O
S10	O
and	O
table	O
S7	O
).	O

We	O
profiled	O
by	O
NanoString	O
analysis	O
the	O
global	O
expression	O
of	O
miRNAs	O
in	O
the	O
mouse	B-OG
Apcfl	O
/	O
fl	O
HCC	B-DS
model	O
.	O

In	O
the	O
hypothesis	O
that	O
uc	O
.	O
158	O
−	O
acts	O
as	O
ceRNA	O
,	O
we	O
searched	O
for	O
miRNAs	O
that	O
were	O
downregulated	O
in	O
Apcfl	O
/	O
fl	O
versus	O
Apc	B-GP
+/+	O
liver	O
tissues	O
(	O
see	O
online	O
supplementary	O
table	O
S7	O
).	O

Among	O
these	O
nine	O
miRNAs	O
,	O
miR	O
-	O
615	O
,	O
miR	O
-	O
193b	O
and	O
miR	O
-	O
346	O
were	O
upregulated	O
after	O
inhibition	O
of	O
uc	O
.	O
158	O
−	O
in	O
HepG2	O
cells	O
,	O
with	O
miR	O
-	O
193b	O
showing	O
the	O
most	O
significant	O
increase	O
and	O
having	O
higher	O
values	O
of	O
expression	O
(	O
figure	O
7A	O
).	O

Indeed	O
,	O
miR	O
-	O
193b	O
was	O
shown	O
to	O
be	O
downregulated	O
in	O
human	B-OG
HCC	B-DS
.	O
39	O
40	O
We	O
observed	O
downregulation	O
of	O
miR	O
-	O
193b	O
also	O
in	O
human	B-OG
CCA	B-DS
tissues	O
in	O
comparison	O
with	O
matched	O
adjacent	O
non	O
-	O
neoplastic	O
tissues	O
(	O
see	O
online	O
supplementary	O
figure	O
S11	O
).	O

miR	O
-	O
193b	O
was	O
found	O
to	O
be	O
overexpressed	O
in	O
Huh	O
-	O
7	O
versus	O
HepG2	O
cells	O
(	O
in	O
line	O
with	O
uc	O
.	O
158	O
−	O
expression	O
)	O
(	O
figure	O
7B	O
).	O

Enforced	O
expression	O
of	O
uc	O
.	O
158	O
−	O
in	O
Huh	O
-	O
7	O
cells	O
induced	O
downregulation	O
of	O
miR	O
-	O
193b	O
(	O
figure	O
7C	O
).	O

Co	O
-	O
transfection	O
of	O
GAP1	O
and	O
anti	O
-	O
miR	O
-	O
193b	O
could	O
rescue	O
the	O
biological	O
effect	O
of	O
uc	O
.	O
158	O
−	O
inhibition	O
on	O
cell	O
viability	O
(	O
figure	O
7D	O
).	O

We	O
then	O
looked	O
at	O
the	O
level	O
of	O
miR	O
-	O
193b	O
in	O
the	O
sera	O
of	O
patients	O
with	O
HCC	B-DS
(	O
n	O
:	O
10	O
)	O
who	O
were	O
naive	O
for	O
any	O
treatment	O
.	O

Patients	O
with	O
low	O
circulating	O
miR	O
-	O
193b	O
had	O
mainly	O
alpha	B-GP
-	I-GP
fetoprotein	I-GP
(	O
AFP	B-GP
)	O
negative	O
tumours	B-DS
,	O
in	O
line	O
with	O
previous	O
reports	O
of	O
observed	O
lower	O
levels	O
of	O
AFP	B-GP
in	O
CTNNB1	B-GP
-	O
mutated	O
HCC41	O
(	O
figure	O
7E	O
).	O

miR	O
-	O
193b	O
expression	O
is	O
dependent	O
on	O
uc	O
.	O
158	O
−	O
expression	O
.	O

HepG2	O
cells	O
were	O
transfected	O
in	O
100	O
mm	O
dishes	O
for	O
48	O
hours	O
,	O
and	O
RNA	O
extracted	O
to	O
assess	O
microRNA	O
expression	O
by	O
TaqMan	O
assays	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
three	O
experiments	O
.	O

(	O
B	O
)	O
miR	O
-	O
193b	O
expression	O
was	O
assessed	O
in	O
Huh	O
-	O
7	O
and	O
HepG2	O
cells	O
.	O

Bars	O
represent	O
logarithmic	O
expression	O
of	O
miR	O
-	O
193b	O
in	O
Huh	O
-	O
7	O
versus	O
HepG2	O
.	O

In	O
three	O
independent	O
experiments	O
,	O
miR	O
-	O
193b	O
expression	O
was	O
higher	O
in	O
Huh	O
-	O
7	O
in	O
comparison	O
with	O
HepG2	O
.	O

(	O
C	O
)	O
Huh	O
-	O
7	O
cells	O
were	O
transfected	O
with	O
a	O
vector	O
overexpressing	O
uc	O
.	O
158	O
−	O
or	O
an	O
empty	O
vector	O
for	O
48	O
hours	O
.	O

Expression	O
of	O
uc	O
.	O
158	O
−	O
and	O
miR	O
-	O
193b	O
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
represent	O
the	O
logarithmic	O
expression	O
of	O
ncRNAs	O
in	O
cells	O
transfected	O
with	O
uc	O
-	O
158	O
−	O
vector	O
compared	O
with	O
empty	O
vector	O
.	O

The	O
downregulation	O
of	O
mR	O
-	O
193	O
is	O
quantitatively	O
comparable	O
with	O
the	O
upregulation	O
achieved	O
in	O
panel	O
A	O
.	O

(	O
D	O
)	O
HepG2	O
cells	O
were	O
transfected	O
with	O
GAPMER	O
control	O
or	O
GAP1	O
alone	O
or	O
in	O
association	O
with	O
anti	O
-	O
miR	O
-	O
193b	O
,	O
and	O
cell	O
viability	O
assessed	O
by	O
CellTiter	O
-	O
Blue	O
at	O
48	O
hours	O
.	O

Bars	O
represent	O
mean	O
±	O
SD	O
of	O
six	O
replicates	O
.	O

(	O
E	O
)	O
Sera	O
were	O
collected	O
from	O
patients	O
with	O
hepatocarcinoma	B-DS
(	O
HCC	B-DS
)	O
naïve	O
for	O
any	O
treatment	O
(	O
n	O
:	O
10	O
),	O
and	O
microRNA	O
extracted	O
using	O
fixed	O
starting	O
volume	O
.	O

miR	O
-	O
193b	O
was	O
assessed	O
by	O
TaqMan	O
assay	O
.	O
χ2	O
test	O
was	O
used	O
to	O
assess	O
the	O
correlation	O
between	O
miR	O
-	O
193b	O
and	O
alpha	B-GP
-	I-GP
fetoprotein	I-GP
(	O
AFP	B-GP
)	O
groups	O
.	O

Discussion	O

It	O
is	O
becoming	O
clear	O
that	O
a	O
large	O
number	O
of	O
lncRNAs	O
have	O
a	O
determining	O
role	O
in	O
regulating	O
normal	O
cell	O
physiology	O
as	O
well	O
as	O
a	O
variety	O
of	O
diseases	O
including	O
cancer	B-DS
.	O
42	O
T	O
-	O
UCRs	O
are	O
long	O
ncRNAs	O
that	O
harbour	O
ultraconserved	O
elements	O
and	O
are	O
altered	O
in	O
human	B-OG
carcinomas	B-DS
.	O

Despite	O
some	O
evidence	O
suggests	O
that	O
DNA	O
methylation	O
and	O
miRNA	O
-	O
mediated	O
regulation	O
may	O
be	O
responsible	O
for	O
their	O
modulation	O
,	O
19	O
20	O
the	O
mechanisms	O
of	O
T	O
-	O
UCR	O
deregulation	O
have	O
been	O
poorly	O
explored	O
.	O

In	O
these	O
studies	O
,	O
we	O
showed	O
that	O
T	O
-	O
UCRs	O
may	O
act	O
downstream	O
of	O
key	O
signalling	O
routes	O
,	O
such	O
as	O
the	O
Wnt	B-GP
pathway	O
,	O
and	O
drive	O
cancer	B-DS
cell	O
growth	O
.	O

Wnt	B-GP
/	O
β	B-GP
-	I-GP
catenin	I-GP
signalling	O
is	O
a	O
key	O
driver	O
in	O
about	O
half	O
of	O
liver	B-DS
cancers	I-DS
,	O
and	O
growing	O
evidence	O
is	O
suggesting	O
that	O
ncRNAs	O
are	O
mediators	O
of	O
this	O
pathway	O
.	O
17	O
43	O
We	O
provide	O
the	O
first	O
evidence	O
that	O
T	O
-	O
UCRs	O
can	O
be	O
dependent	O
on	O
Wnt	B-GP
activation	O
in	O
a	O
species	O
-	O
conserved	O
fashion	O
.	O

In	O
addition	O
,	O
our	O
studies	O
showed	O
that	O
uc	O
.	O
158	O
−	O
is	O
activated	O
only	O
in	O
cancer	B-DS
cells	O
,	O
suggesting	O
it	O
may	O
be	O
specific	O
for	O
Wnt	B-GP
activation	O
that	O
should	O
be	O
targeted	O
for	O
an	O
antitumoural	O
effect	O
.	O

Indeed	O
,	O
Wnt	B-GP
inhibitor	O
exploitation	O
has	O
been	O
limited	O
by	O
toxicity	O
,	O
and	O
activation	O
of	O
the	O
Wnt	B-GP
pathway	O
in	O
cirrhotic	O
liver	O
may	O
preclude	O
the	O
use	O
of	O
these	O
drugs	O
in	O
patients	O
with	O
liver	B-DS
cancer	I-DS
.	O

Conversely	O
,	O
the	O
identification	O
of	O
a	O
cancer	B-DS
-	O
specific	O
mediator	O
of	O
the	O
pathway	O
may	O
improve	O
the	O
potential	O
of	O
designing	O
novel	O
and	O
more	O
selective	O
drugs	O
.	O

Interestingly	O
,	O
we	O
have	O
shown	O
that	O
molecular	O
traits	O
,	O
such	O
as	O
overexpression	O
of	O
uc	O
.	O
158	O
−,	O
may	O
be	O
present	O
across	O
tumour	B-DS
types	O
independently	O
on	O
site	O
of	O
origin	O
.	O

These	O
findings	O
inform	O
us	O
that	O
T	O
-	O
UCRs	O
may	O
either	O
be	O
used	O
as	O
tissue	O
-	O
specific	O
biomarkers	O
,	O
as	O
in	O
the	O
case	O
of	O
TUC338	O
,	O
25	O
or	O
may	O
be	O
commonly	O
deregulated	O
across	O
tumour	B-DS
types	O
,	O
such	O
as	O
uc	O
.	O
158	O
−.	O

Inclusion	O
criteria	O
with	O
regard	O
to	O
tumour	B-DS
origin	O
(	O
ICC	B-DS
vs	O
ECC	B-DS
)	O
are	O
still	O
a	O
debateable	O
question	O
in	O
the	O
design	O
of	O
clinical	O
trials	O
in	O
CCA	B-DS
.	O

However	O
,	O
based	O
on	O
these	O
studies	O
,	O
we	O
may	O
suggest	O
that	O
clinical	O
trials	O
should	O
be	O
designed	O
on	O
the	O
bases	O
of	O
molecular	O
and	O
genomic	O
features	O
instead	O
of	O
tumour	B-DS
site	O
,	O
and	O
may	O
even	O
include	O
ICC	B-DS
and	O
HCC	B-DS
for	O
selective	O
drugs	O
that	O
target	O
commonly	O
deregulated	O
pathways	O
.	O

As	O
per	O
the	O
reason	O
why	O
uc	O
.	O
158	O
−	O
is	O
aberrantly	O
deregulated	O
in	O
malignant	O
hepatocytes	O
and	O
cholangiocytes	O
,	O
we	O
may	O
speculate	O
that	O
uc	O
.	O
158	O
−	O
overexpressing	O
hepatic	B-DS
cancer	I-DS
stem	O
cells	O
may	O
give	O
rise	O
to	O
specific	O
subtypes	O
of	O
HCC	B-DS
and	O
CCA	B-DS
in	O
the	O
presence	O
of	O
Wnt	B-GP
pathway	O
.	O

However	O
,	O
we	O
cannot	O
exclude	O
that	O
the	O
plasticity	O
of	O
mature	O
hepatocytes	O
to	O
differentiate	O
in	O
cholangiocytes	O
may	O
justify	O
some	O
common	O
traits	O
acquired	O
during	O
liver	O
carcinogenesis	O
.	O
44	O
45	O
Another	O
potential	O
explanation	O
relies	O
on	O
the	O
evidence	O
that	O
stroma	O
is	O
an	O
important	O
Wnt	B-GP
activator	O
even	O
in	O
tumours	B-DS
,	O
such	O
as	O
CCA	B-DS
,	O
that	O
lack	O
CTNNB1	B-GP
mutations	O
.	O
27	O
35	O
Thus	O
,	O
further	O
studies	O
are	O
warranted	O
to	O
explore	O
the	O
involvement	O
of	O
the	O
stroma	O
-	O
induced	O
activation	O
of	O
uc	O
.	O
158	O
−	O
driven	O
carcinogenesis	O
.	O

The	O
mechanism	O
of	O
function	O
of	O
T	O
-	O
UCRs	O
is	O
still	O
not	O
clearly	O
elucidated	O
.	O

Previous	O
evidence	O
suggests	O
that	O
they	O
may	O
act	O
as	O
decoy	O
molecules	O
for	O
miRNAs	O
.	O
38	O
We	O
provided	O
data	O
in	O
support	O
of	O
this	O
hypothesis	O
.	O

We	O
have	O
previously	O
shown	O
that	O
miR	O
-	O
193b	O
mediates	O
apoptosis	O
through	O
targeting	O
of	O
mcl	B-GP
-	I-GP
1	I-GP
,	O
12	O
and	O
the	O
overexpression	O
of	O
uc	O
.	O
158	O
−	O
in	O
HCC	B-DS
nicely	O
fits	O
with	O
these	O
data	O
as	O
well	O
as	O
with	O
the	O
previous	O
work	O
that	O
found	O
downregulation	O
of	O
miR	O
-	O
193b	O
in	O
a	O
subgroup	O
of	O
HCCs	B-DS
.	O
39	O
40	O
It	O
is	O
increasingly	O
recognised	O
that	O
cancer	B-DS
cells	O
rely	O
on	O
a	O
complex	O
network	O
of	O
transcripts	O
generated	O
from	O
coding	O
and	O
non	O
-	O
coding	O
genes	O
,	O
and	O
that	O
interplay	O
of	O
different	O
RNA	O
classes	O
drives	O
cancer	B-DS
progression	O
more	O
than	O
a	O
single	O
aberration	O
.	O
46	O
However	O
,	O
identification	O
of	O
a	O
single	O
molecule	O
representing	O
the	O
activation	O
of	O
a	O
network	O
may	O
prove	O
more	O
useful	O
for	O
the	O
identification	O
of	O
therapeutic	O
targets	O
and	O
for	O
the	O
implementation	O
of	O
screening	O
technologies	O
to	O
be	O
adopted	O
for	O
targeted	O
therapy	O
.	O

Ethics	O
approval	O
:	O
Different	O
bodies	O
as	O
specified	O
in	O
the	O
text	O
.	O

Provenance	O
and	O
peer	O
review	O
:	O
Not	O
commissioned	O
;	O
externally	O
peer	O
reviewed	O
.	O

